

## Update on the Dengue situation in the Western Pacific Region

This report describes the epidemiology of dengue in the World Health Organization Western Pacific Region. Data are compiled from open sources (national indicator-based surveillance systems) with the exception of Cambodia, Lao People’s Democratic Republic and Viet Nam, where data are provided by the WHO Country Offices. For the Pacific Island Countries, syndromic surveillance data are provided by the WHO Division of Pacific Technical Support. Information is reported based on countries’ standard dengue case definitions, summary of these definitions and countries’ dengue surveillance systems - included as an annex to this report. Due to differences in surveillance methods and reporting practices, a comparison of trends between countries and areas is not possible, however, national trends can be observed over time.

### Northern Hemisphere

#### Cambodia

From 1 January to 31 December 2024, the National Dengue Surveillance System reported a total of 18 983 cases with 46 deaths (Case Fatality Rate (CFR) 0.24%) (Figure 1). This is lower than the number of cases and deaths reported in 2023: 35 390 cases and 90 deaths.





Figure 1: Weekly dengue cases in 2024 with endemic and epidemic alert thresholds in Cambodia

Source: National Dengue Surveillance System (NDSP/CNM/MOH)

#### China


In November 2024, a total of 5 201 dengue cases were reported in China, a decrease from 11 083 cases reported in October 2024. There have been a total of 23 888 dengue cases including no deaths reported since the beginning of 2024, with a larger peak observed in the number of reported cases, occurring slightly later than usual, compared to previous years (Figure 2).



**Figure 2: Dengue cases reported monthly from 2019-2024 (as of November 2024) in China**  
 Source: [National Disease Control and Prevention Administration, China](#)

### Lao People’s Democratic Republic

In epidemiological week 52 of 2024 (23 to 29 December 2024), 100 dengue cases and no deaths were reported (Figure 3), a decrease from 106 cases in epidemiological week 51 and 195 cases in week 50. The cumulative number of cases reported in 2024 (as of epidemiological week 52) is 19 486, which is lower than during the same period in 2023 (n=32 109).




**Figure 3: Dengue cases reported weekly from 2019-2024 in Lao PDR**  
 Source: [National Centre for Laboratory and Epidemiology, Ministry of Health, Lao PDR](#)

## Malaysia

In epidemiological week 52 of 2024 (22 to 28 December 2024), a total of 1 341 cases were reported, a decrease compared to 1 407 cases in week 51. The cumulative year-to-date number of dengue cases as of week 52 is 122 423 cases, which is lower than during the same period in 2023 (n=123 133). One additional dengue-related death was reported in week 52, bringing the cumulative number in 2024 to 117 deaths, 17% higher than the number recorded in 2023 (n=100).

\*Figure 4 is based on data updated as of 31 October 2024. No updates have been available since then.




**Figure 4: Dengue cases reported weekly from 2023, 2024 and median 2019-2023 in Malaysia**

Source: Department of Health, Malaysia

Note: Last updated as of 31 October 2024. Data is subject to change.

## Singapore

In epidemiological week 52 of 2024 (22 to 28 December 2024), a total of 74 dengue cases including one dengue haemorrhagic fever case were reported in Singapore. Cumulatively, a total of 13 655 cases (Figure 5) have been reported this year, a 37.2% increase compared to the same period in 2023 (n=9 949). Preliminary results of all positive dengue samples serotyped in December 2024 showed DEN-1, DEN-2, DEN-3 and DEN-4 at 6.8%, 63.2%, 26.3% and 3.8%, respectively.




**Figure 5: Dengue cases reported weekly from 2019-2024 (as of 28 December 2024) in Singapore**

Source: Communicable Diseases Division, Ministry of Health, Singapore

Note: Case numbers are derived from the MOH Singapore's weekly-infectious-disease-bulletin-year-2024\_upload as available from [MOH | Weekly Infectious Diseases Bulletin](#)

## Viet Nam

In epidemiological week 50 (9 to 15 December 2024), a total of 4 431 cases were reported, with one death. Compared to the previous week (5 244 cases), the number of cases has decreased by 15.5%. As of 15 December 2024, there have been 138 342 cases including 26 deaths reported this year, which is a 17.4% decrease in cases and a 43.5% decrease in deaths compared to the same period in 2023 (167 437 cases and 46 deaths). During epidemiological week 50, 3 374 cases were hospitalized (76.1%), marking a 14% decrease compared to the previous week (Figure 6).



**Figure 6: Number of dengue hospital admissions and deaths by weeks in 2024 compared to 2023, as of week 50, 2024, Viet Nam**


*Source: General Department of Preventive Medicine, Ministry of Health, Viet Nam*

Note hospitalizations include inpatients and outpatients. The alert threshold is a 5-year mean plus 2 standard deviations.

## Southern Hemisphere

### Australia

From 1 to 31 December 2024, a total of 102 dengue cases were reported in Australia. Cumulatively, a total of 2 298 dengue cases have been reported in 2024, which is more than double the number of cases reported during the same period in 2023 (1 122 cases) (Figure 7).



**Figure 7: Laboratory-confirmed dengue cases reported monthly from 2019-2024 in Australia**

*Source: Department of Health, Australia*

Note: Graph was updated as of 31 October 2024. Data is subject to change.

## Pacific Islands Countries

### New Caledonia

As of 31 December 2024, a total of 11 dengue cases have been reported in 2024 in New Caledonia (Figure 8). Of those 11 cases, three were locally acquired confirmed cases (DENV-1 and DENV-2), six were imported (DENV-1 and DENV-2), and the rest were probable local cases. Currently, there is no ongoing dengue outbreak in New Caledonia.















Figure 8: Dengue cases reported by month from 1 January 2022 to 31 December 2024 in New Caledonia


Source: Network of sentinel physicians, New Caledonia

### Pacific Island Countries and Areas (PICs) – Dengue-like illness (DLI) Surveillance

There is no update for this reporting period. Among the PICs with available surveillance data (18/21 PICs), an upward trend of DLI cases was reported in Fiji, French Polynesia and Solomon Islands in week 38 (ending 23 September), and a downward trend of DLI cases was reported in Micronesia, Federated States of (FSM). The remaining PICs reported either no or low numbers of DLI cases or provided no updates (Figure 9).







**Figure 9. Reported cases of dengue-like illness in Pacific Islands Countries and Areas**

*Source: WHO Division of Pacific Technical Support*

Note: Caution should be taken in interpreting these data as there may be changes in the number of sentinel sites reporting to the Pacific Syndromic Surveillance System (PSSS). Furthermore, the syndromic case definition of DLI may capture cases with non-dengue acute febrile illnesses (AFI) with similar clinical manifestations to dengue. This includes AFI such as chikungunya, influenza, hantavirus, leptospirosis, malaria, measles, paratyphoid and typhoid fevers, scrub typhus, yellow fever, zika, other diseases. The PSSS may also capture dengue cases under 'prolonged fever' surveillance. Alert threshold for DLI is twice the average number of cases seen in the previous 3 weeks.

## Annex 1. Summary of dengue case definitions, laboratory sampling and testing methods used for surveillance in Member States

Country	Case definition		Surveillance system	Laboratory sampling and testing method	Reference
	Clinically confirmed case	Laboratory confirmation required	Description		
Australia	Fever, headache, arthralgia, myalgia, rash, nausea and vomiting	Yes	Dengue is a nationally notifiable disease and cases are monitored through the National Notifiable Diseases Surveillance System (NNDSS) indicator-based surveillance system.	<p>Both confirmed and probable cases are nationally notifiable. A confirmed case requires both laboratory definitive evidence and clinical evidence. A probable case requires either laboratory suggestive evidence and clinical evidence and epidemiological evidence, or clinical evidence and household epidemiological evidence.</p> <p>Laboratory definitive evidence:</p> <ul style="list-style-type: none"> <li>- Isolation of dengue virus, or</li> <li>- Detection of dengue virus by nucleic acid testing, or</li> <li>- Detection of NS1 antigen in the blood by EIA, or</li> <li>- IgG seroconversion or significant increase in antibody level or fourfold or greater rise in titre to dengue virus (proof by neutralization or another specific test)</li> <li>- Detection of dengue virus-specific IgM in cerebrospinal fluid, in the absence of IgM to Murray valley encephalitis, West Nile virus/Kunjin, or Japanese encephalitis viruses.</li> </ul> <p>Laboratory suggestive evidence:</p> <ul style="list-style-type: none"> <li>- Detection of NS1 antigen in blood by rapid antigen test, or</li> <li>- Detection of dengue virus-specific IgM in blood</li> </ul> <p>Epidemiological evidence:</p> <ul style="list-style-type: none"> <li>- Exposure between 3 – 14 days prior to onset either in a country with known dengue activity or in a dengue-receptive area in Australia where a locally-acquired or imported case has been documented with onset within a month.</li> </ul>	1



				Household epidemiological evidence: - Living in the same house as a locally-acquired case in a dengue-receptive area of Australia within a month of onset in the case and at least one case in the chain of epidemiologically linked cases is laboratory confirmed.	
<b>Cambodia</b>	<p>Suspected dengue: very high fever at 39-40 degrees celcius for 2-7 days (usually 3-4 days), with 2 or more of the following signs: flushed face, headache, retro-orbital pain, myalgia/arthralgia, cutaneous rash, haemorrhagic signs (petechiae, positive tourniquet test), and leucopenia.</p> <p>Probable dengue: signs of suspected dengue plus laboratory test results (see right column)) or that the case occurred in an area where the dengue case has been confirmed.</p>	Yes	<p>National Dengue Control Program (NDCP) enhanced sentinel surveillance system</p> <p>Communicable Disease Control (CDC) syndromic surveillance system (CamEWARN).</p> <p>Health Management Information System (HMIS) collects data on confirmed cases and deaths.</p>	<p>Data collected for Cambodia Laboratory Information System (CamLIS), comprised of 32 participating hospital laboratories where NS1 detection is conducted.</p> <p>Laboratory testing: Antibody HI<math>\geq</math> 1/1280 or IgM/IgG positive by ELISA test in convalescence serum</p>	2
<b>China</b>	<p>1) Typical dengue fever can be diagnosed with any of the following conditions:</p> <ul style="list-style-type: none"> <li>- General clinical symptoms of dengue fever, with an epidemiological history (having been to an area where dengue fever is prevalent within 14 days before onset), or living or working in an area where dengue fever cases have occurred within the past month, and with reduced white blood cell count and platelet count (below <math>100 \times 10^9/L</math>)</li> <li>- No epidemiological history, but with a rash, bleeding tendency, and positive IgG or IgM antibodies in a single serum sample.</li> </ul>	No	Reported to the Chinese Centre for Disease Control and Prevention (China CDC) through the Chinese National Notifiable Infectious Disease Reporting Information System (CNNDS).	<p>A clinically diagnosed case with any of the of the following laboratory findings:</p> <ul style="list-style-type: none"> <li>- Isolation of the dengue virus from the serum, cerebrospinal fluid, blood cells, or tissues of an acute-phase patient</li> <li>- Detection of dengue virus gene sequence by RT-PCR or real-time fluorescent quantitative PCR</li> <li>- Detection of dengue virus NS1 antigen in serum from an acute-phase patient</li> <li>- A fourfold or greater increase in specific antibody titer in the convalescent phase compared to the acute phase.</li> </ul>	3, WHO internal communication

	<p>2) Dengue Hemorrhagic Fever can be diagnosed when accompanied by any of the following clinical symptoms:</p> <ul style="list-style-type: none"> <li>- Bleeding tendency, significant bleeding manifestations (such as gastrointestinal bleeding or hemorrhage in the chest, abdomen, or cranium), hepatomegaly, and ascites; and</li> <li>- Laboratory findings including thrombocytopenia (platelet count below <math>100 \times 10^9/L</math>), hemoconcentration (an increase in hematocrit of more than 20% above normal levels or a decrease of more than 20% after fluid resuscitation), and hypoalbuminemia.</li> </ul> <p>3) Dengue Shock Syndrome: Patients with dengue hemorrhagic fever presenting with cold and clammy skin, restlessness, rapid and weak pulse, low blood pressure with a narrow pulse pressure (less than 20mmHg or 2.7kPa), and reduced urine output.</p>				
<b>Lao People's Democratic Republic</b>	WHO dengue case classification (2009) †	No	National Surveillance System for Notifiable Selected Diseases, indicator-based surveillance system that consists of passive weekly reports of clinically suspected cases, on admission, from all health-care facilities across the country.		4
<b>Malaysia</b>	WHO dengue case classification (2009) †	Yes	National Dengue Surveillance System, indicator-based surveillance system	All suspected cases are to be tested by the following laboratory tests: Rapid Combo Test (RCT) (NS1, IgM, IgG), Dengue Antigen and Serology tests by ELISA, Dengue Viral RNA Detection (Real time RT-PCR), Viral Isolation	5
<b>Philippines</b>	WHO dengue case classification (2009) †	Yes	Philippine Integrated Disease Surveillance and Response (PIDSRS), indicator-based surveillance system. Reporting delays of 2-3 weeks, making comparison of current weekly and cumulative figures with previous years difficult.	Confirmed dengue is a suspect case with positive (+) viral culture isolation and/or PCR. NS1 (+), IgM is used to identify probable dengue.	6, 7, 8

<b>Singapore</b> (endemic)	Fever, headache, backache, myalgia, rash, abdominal discomfort and thrombocytopenia and laboratory testing (see right column)	Yes	Dengue is a legally notifiable disease in Singapore and notifying the Ministry of Health should not be later than 24 hours from the time of diagnosis.	Laboratory confirmation is done using standard diagnostic tests for the detection of dengue NS1 antigen, IgM and IgG, or RT-PCR.	9, 10
<b>Viet Nam</b> (endemic)	Acute onset of fever continuously lasting from 2-7 days AND at least 2 of the following: haemorrhagic manifestation /presentation; headache, loss of appetite, nausea, vomiting; rash; muscle pain, joint pain, orbital pain; lethargy; abdominal pain.	No		As per the MOH dengue surveillance guideline, in routine surveillance MAC-ELISA is conducted for at least 7% and virus isolation is conducted for at least 3% of clinical cases. In an outbreak, at least 5 to 10 suspected cases are tested.	11
<b>Pacific Island Countries</b>	WHO dengue case classification (2009) †	No	Pacific Syndromic Surveillance System	Confirmed case: Isolation of dengue virus or detection of dengue-specific antigen or antibodies in tissue, blood, CSF or other body fluid by an advanced laboratory test	12

Only the minimum criteria required for fulfilling a clinical dengue case definition are included here; additional signs and symptoms required for more severe forms are not listed.

† **A probable dengue case** is defined as any case living in or travel to dengue endemic area with fever and two or more of the following: nausea, vomiting, rash, aches and pains, positive tourniquet test, leucopenia and any warning sign. A case with warning signs is defined as a clinically diagnosed case with any of the following: abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleed, lethargy, restlessness, liver enlargement > 2 cm and increase in haematocrit concurrent with rapid decrease in platelet count. **Severe dengue** is defined as severe plasma leakage leading to any of the following: shock, fluid accumulation with respiratory distress OR severe bleeding as evaluated by clinician OR severe organ involvement of liver (aspartate amino transferase or alanine amino transferase ≥ 1000), central nervous system (impaired consciousness) or heart and other organs.<sup>10</sup>

#### References:

1. Australian Government Department of Health AGDo. Dengue virus infection surveillance and case definition [updated 14 June 2022 and 1 January 2018 respectively] Available from: <https://www.health.gov.au/diseases/dengue-virus-infection>, and <https://www.health.gov.au/sites/default/files/documents/2022/06/dengue-virus-infection-surveillance-case-definition.pdf>
2. Cambodia Ministry of Health NCFP, Entomology and Malaria Control. National Guideline for Clinical Management of Dengue, 2018. 2018. Available from: [https://niph.org.kh/niph/uploads/library/pdf/GL055\\_National\\_guideline\\_for\\_CIM\\_Dengue.pdf](https://niph.org.kh/niph/uploads/library/pdf/GL055_National_guideline_for_CIM_Dengue.pdf).
3. China CDC. Dengue surveillance guideline. Available from: [https://www.chinacdc.cn/jkzt/crb/zt/dgr/jszl\\_2235/201810/P020181010391462131548.pdf](https://www.chinacdc.cn/jkzt/crb/zt/dgr/jszl_2235/201810/P020181010391462131548.pdf)
4. Khampapongpane B, Lewis HC, Ketmayoon P, Phonekeo D, Somoulay V, Khamsing A, et al. National dengue surveillance in the Lao People's Democratic Republic, 2006-2012: epidemiological and laboratory findings. Western Pac Surveill Response J. 2014;5(1):7-13. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/24734212>.
5. Ministry of Health Malaysia DCD. Case definitions for infectious diseases in Malaysia. 2017. Available from: [https://www.moh.gov.my/moh/resources/Penerbitan/Garis%20Panduan/Pengurusan%20KEsihatan%20&%20kawalan%20pykit/Case\\_Definition\\_Of\\_Infectious\\_Disease\\_3rd\\_Edition\\_2017.pdf](https://www.moh.gov.my/moh/resources/Penerbitan/Garis%20Panduan/Pengurusan%20KEsihatan%20&%20kawalan%20pykit/Case_Definition_Of_Infectious_Disease_3rd_Edition_2017.pdf)
6. Secretary PDoHOot. Guidelines for the Nationwide Implementation of Dengue Rapid Diagnostic Test (RDT), Administrative order No.2016-0043. 2016(2016-0043).
7. Secretary PDoHOot. Revised Dengue Clinical Case Management Guidelines 2011, Administrative order No.2012-0006. 2012 22 March 2012. Report No.
8. Diseases SNCfI. Diseases and Conditions, Dengue 2020 [updated 14 September 2020. Available from: <https://www.doh.gov.ph/Health-Advisory/Dengue>.
9. National Centre for Infectious Diseases, Dengue. Available from: <https://www.ncid.sg/Health-Professionals/Diseases-and-Conditions/Pages/Dengue.aspx>
10. National Environment Agency. Surveillance and Epidemiology Programme [updated 21 April 2023]. Available from: <https://www.nea.gov.sg/corporate-functions/resources/research/surveillance-and-epidemiology-programme#Ehi%20Diagnostics%20Unit>

11. Viet Nam Ministry of Health VNMo. Circular 54/2015 / TT-BYT 2015 [updated 26 April 2016. Available from: <https://syt.thuathienhue.gov.vn/?gd=27&cn=108&tc=3993>.
12. Pacific Islands Outbreak Manual. Available from: <https://www.pphsn.net/resources/outbreak-manual/>
13. WHO dengue outbreak toolbox. Available from: [https://www.who.int/docs/default-source/outbreak-toolkit/updates-documents\\_july-5/dengue-outbreak-data-collection-toolbox---inis-3-july-1.pdf?sfvrsn=ec3ffc3\\_2](https://www.who.int/docs/default-source/outbreak-toolkit/updates-documents_july-5/dengue-outbreak-data-collection-toolbox---inis-3-july-1.pdf?sfvrsn=ec3ffc3_2)